74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Viatris Inc
Closed
SectorHealthcare
8.03 2.69
Overview
Share price change
24h
Min
7.82
Max
8.12
Income | -611M -517M |
|---|---|
Sales | -210M 3.5B |
EPS | 0.54 |
Dividend yield | 6.34 |
Profit margin | -14.64 |
Employees | 32,000 |
EBITDA | -566M 340M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +33.87% upside |
Dividend yield Sector Avg | 6.34% 2.63% |
|---|---|
Next Earnings | 8 May 2025 |
Next Dividend date | 13 Jun 2025 |
Next Ex Dividend date | 22 May 2025 |
Market Cap | -4.6B 9B |
|---|---|
Previous open | 5.34 |
Previous close | 8.03 |
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
Viatris Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Viatris Inc Forecast
Price Target
By TipRanks
33.87% upside
12 Months Forecast
Average 10.75 USD 33.87%
High 13 USD
Low 8 USD
Based on 4 Wall Street analysts offering 12 month price targets forViatris Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Viatris Inc
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
